Skip to main content
HRMY
NASDAQ Life Sciences

Harmony 10-Q: Q3 Revenue $268.9M, $1.05B Cash, R&D Up 30% on MSN Milestone

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$35.94
Mkt Cap
$2.156B
52W Low
$25.902
52W High
$43.49
52W Position info
39% above low
Off High info
17% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

HRMY sits 39% above its 52-week low of $25.902.

Summary

Harmony's Q3 10-Q confirms $268.9 million of revenue (+12%) but shows gross margin slipping to 70% on new Novitium royalties and R&D up 30% on a $25 million MSN milestone charge, backed by $1.05 billion of cash and investments.


Key Events · Earnings and Guidance · HRMY

  • Q3 Revenue $268.9M, Up 12.3%

    Net product revenue rose to $268,917 thousand from $239,455 thousand, driven by a 7.5% increase in units shipped and a 7% January 2026 price increase, partly offset by higher rebates.

  • Gross Margin Slips to 70%

    Cost of product sold rose 35.3% to $80,686 thousand, or 30.0% of net product revenue versus 24.9% a year earlier, primarily on new royalties from the Novitium License Agreement.

  • R&D Up 30% on MSN Milestone

    Research and development expense rose to $71,663 thousand from $54,962 thousand, including a $25.0 million IPR&D charge for the MSN patent milestone achieved in September 2026.

  • $1.05B Cash; Covenant Default Waived

    Cash, cash equivalents and investments totaled $1,051,605 thousand against $150.0 million of debt; the July 2025 nonfinancial covenant default was waived on May 4, 2026 and the company is in compliance as of September 30, 2026.


Analysis · HRMY · Life Sciences

The headline numbers already hit the tape this morning via the 8-K, but the 10-Q is where the quality-of-earnings detail lives. Revenue grew 12.3% to $268.9 million, yet gross margin compressed: cost of product sold jumped to 30.0% of revenue from 24.9% a year ago, driven by new Novitium royalties. R&D rose 30.4% to $71.7 million, largely a $25.0 million MSN patent milestone charge. Nine-month operating cash flow of $196.9 million came in below last year's $222.0 million despite higher net income, as receivables and other working capital absorbed cash. Against that, the balance sheet is a fortress: $1.05 billion of cash and investments against $150.0 million of debt, with the July 2025 covenant default formally waived in May 2026. The one item investors should track is the AET patent fight: a preliminary injunction hearing is set for January 26, 2027, with a decision expected by February 14, 2027, and that outcome bears directly on the WAKIX exclusivity timeline.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, HRMY was trading at $35.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $25.90 to $43.49. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HRMY - Latest Insights

HRMY
Nov 04, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.18
Real-time Price: $33.11 info
Change: -$3.07 (-8%) info
Market Cap: $1.944B info
HRMY
Nov 04, 2026, 7:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $36.50
Real-time Price: $33.11 info
Change: -$3.39 (-9%) info
Market Cap: $1.944B info
HRMY
Oct 22, 2026, 3:57 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $36.03
Real-time Price: $33.11 info
Change: -$2.92 (-8%) info
Market Cap: $1.944B info
HRMY
Oct 13, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $38.40
Real-time Price: $33.11 info
Change: -$5.29 (-14%) info
Market Cap: $1.944B info
HRMY
Oct 12, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $40.28
Real-time Price: $33.11 info
Change: -$7.17 (-18%) info
Market Cap: $1.944B info